Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Scott Hessen

Clinical Cardiac Electrophysiology Philadelphia, PA Medical Doctor

NPI 1184697914 CMS profile 98541

525 Jamestown St Ste 107, Philadelphia, PA 19128

Open in the dashboard

General payments

$12,504

105 records reported · program years 2019–2025

Research payments

$5,479

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$11,635 paid to institutions, not to them · program year 2019

Through program year 2025, Scott Hessen of Philadelphia, PA is reported in the CMS Open Payments database as having received $12,504 across 105 general payments and $5,479 in research payments paid to them. Separately, studies naming them as principal investigator received $11,635 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 49th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $622 26
2025 Research $5,479 2
2024 General $744 22
2023 General $982 22
2022 General $866 20
2021 General $390 6
2020 General $3,296 1
2019 General $5,605 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Scott Hessen
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Scott Hessen were reported at $622. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Scott Hessen Clinical Cardiac Electrophysiology median Middle half National median
2019 $5,605 $2,361 $585–$8,260 $163
2020 $3,296 $993 $247–$4,351 $114
2021 $390 $1,185 $326–$4,739 $132
2022 $866 $2,073 $554–$6,789 $149
2023 $982 $2,568 $759–$8,159 $160
2024 $744 $2,557 $703–$7,403 $164
2025 $622 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sanofi-Aventis U.S. LLC $8,336 7 payments
  2. Janssen Pharmaceuticals, Inc $1,824 22 payments
  3. Pfizer Inc. $223 11 payments
  4. Novartis Pharmaceuticals Corporation $212 10 payments
  5. Amgen Inc. $140 8 payments
  6. Impulse Dynamics (USA) Inc. $135 1 payment
  7. Edwards Lifesciences Corporation $131 1 payment
  8. Endotronix, Inc. $127 1 payment
  9. AstraZeneca Pharmaceuticals LP $119 5 payments
  10. Kaneka Pharma America LLC $112 1 payment
  11. Other $1,145 38 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $8,146 2 payments
  2. Food and Beverage $4,358 103 payments
Products named General payments · program years 2019–2025
  1. DISEASE STATE $4,971 2 payments
  2. MULTAQ $3,296 1 payment
  3. XARELTO $1,824 22 payments
  4. LEQVIO $194 9 payments
  5. OPTIMIZER SMART SYSTEM $135 1 payment
  6. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $131 1 payment
  7. CORDELLA PULOMONARY ARTERY PRESSURE SENSOR $127 1 payment
  8. VYNDAQEL $111 5 payments
  9. ENSITE PRECISION $111 1 payment
  10. MoMe Kardia $106 1 payment
  11. Other $1,354 61 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Amgen Inc. $5,479 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 45 drugs

Part D claims

2,574

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$530,437

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

25.6%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 202 $224,563
Xarelto Rivaroxaban Brand 113 $143,291
Entresto Sacubitril/Valsartan Brand 67 $89,395
Jardiance Empagliflozin Brand 23 $20,429
Farxiga Dapagliflozin Propanediol Brand 14 $12,025
Dofetilide Generic 18 $6,615
Metoprolol Succinate Generic 261 $3,734
Atorvastatin Calcium Generic 251 $3,323
Ezetimibe Generic 76 $2,900
Rosuvastatin Calcium Generic 137 $2,411

The 10 drugs with the highest cost, of 45 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$544,110

Medicare's payments for the services billed

Medicare patients

1,219

Average age 75

Services billed

5,753

586 women, 633 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 55%
Arthritis 47%
Atrial fibrillation 46%
Chronic kidney disease 37%
Diabetes 33%
Heart failure 32%
Depression 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $148
$148 113 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $72
$72 — —
Repatha
  • Amgen Inc. $38
$38 — —
NEXLETOL
  • Esperion Therapeutics, Inc. $33
$33 — —
VYNDAQEL
  • PFIZER INC. $24
$24 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

107 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record